Mylan Delays Restructuring Amid COVID-19
Follows Postponement Of Merger With Pfizer’s Upjohn Business
Mylan has delayed a major restructuring program ahead of its planned merger with Pfizer’s Upjohn unit due to the impact of the COVID-19 pandemic, which at the same time brought tailwinds for the firm’s first-quarter results.
